Katzman M, Meade W, Iglar K, Rachlis A, Berger P, Chan C K
Department of Medicine, Wellesley Hospital, Sunnybrook Medical Center, Canada.
Chest. 1992 Jan;101(1):79-81. doi: 10.1378/chest.101.1.79.
A systematic evaluation of changes in pulmonary status by objective spirometric assessment and subjective rating using visual analog scale was performed in a cohort of 134 patients receiving aerosolized pentamidine (AP) for the prevention of Pneumocystis carinii pneumonia. Significant bronchospasm defined as greater than or equal to 15 percent reduction in the forced expiratory volume in 1 s was noted in 26 of 100 (26 percent) of patients receiving AP alone. Despite the use of salbutamol (albuterol) as concurrent aerosolized treatment in 34 subjects, bronchospasm developed in 9 of 34 (26 percent) of the patients. The subjective respiratory status rating scale was found to be unreliable in correctly predicting the development of bronchospasm. We conclude that a high incidence of bronchospasm is present in patients receiving regular AP administration using an ultrasonic nebulizer as studied, and concurrent administration of salbutamol is not fully protective of this acute adverse pulmonary reaction.
对134例接受雾化喷他脒（AP）预防卡氏肺孢子虫肺炎的患者进行了一项系统评估，采用客观肺量计评估和视觉模拟量表进行主观评分，以评估肺部状态变化。在100例单独接受AP治疗的患者中，有26例（26%）出现了显著的支气管痉挛，定义为一秒用力呼气量减少大于或等于15%。尽管在34名受试者中同时使用沙丁胺醇进行雾化治疗，但34例患者中有9例（26%）出现了支气管痉挛。主观呼吸状态评分量表在正确预测支气管痉挛的发生方面不可靠。我们得出结论，在所研究的使用超声雾化器定期给予AP的患者中，支气管痉挛的发生率很高，同时给予沙丁胺醇并不能完全预防这种急性不良肺部反应。
